Jiangsu Hualv Biological Technology Co.Ltd.
Jiangsu Chinagreen Biological Technology Group Co.,Ltd. engages in the research, development, factory cultivation, and sale of edible fungi in China. It offers Flammulina velutipes; Pleurotus eryngii, including white jade mushroom and oyster mushroom; and Maitake mushrooms. The company was founded in 2010 and is headquartered in Suqian, China.
Jiangsu Hualv Biological Technology Co.Ltd. (300970) - Total Assets
Latest total assets as of June 2025: CN¥2.25 Billion CNY
Based on the latest financial reports, Jiangsu Hualv Biological Technology Co.Ltd. (300970) holds total assets worth CN¥2.25 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jiangsu Hualv Biological Technology Co.Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how Jiangsu Hualv Biological Technology Co.Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jiangsu Hualv Biological Technology Co.Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu Hualv Biological Technology Co.Ltd.'s total assets of CN¥2.25 Billion consist of 25.2% current assets and 74.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.7% |
| Accounts Receivable | CN¥16.70 Million | 0.7% |
| Inventory | CN¥196.07 Million | 8.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥58.02 Million | 2.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Jiangsu Hualv Biological Technology Co.Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Hualv Biological Technology Co.Ltd.'s current assets represent 25.2% of total assets in 2024, a decrease from 29.7% in 2019.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2024, up from 12.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 5.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 8.5% of total assets.
Jiangsu Hualv Biological Technology Co.Ltd. Competitors by Total Assets
Key competitors of Jiangsu Hualv Biological Technology Co.Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Matang Bhd
KLSE:0189
|
Malaysia | RM256.56 Million |
|
Local Bounti Corp
NYSE:LOCL
|
USA | $417.76 Million |
|
Pinago Utama Tbk Pt
JK:PNGO
|
Indonesia | Rp1.68 Trillion |
|
Milae Bioresources Co. Ltd
KQ:218150
|
Korea | ₩64.51 Billion |
|
Wanxiang Doneed Co Ltd
SHG:600371
|
China | CN¥725.38 Million |
|
ShenZhen Kondarl Group Co Ltd
SHE:000048
|
China | CN¥10.49 Billion |
|
Guangdong Guanghong Holdings Co Ltd
SHE:000529
|
China | CN¥6.82 Billion |
|
Hunan Zhenghong Science and Technology Develop Co Ltd
SHE:000702
|
China | CN¥505.58 Million |
Jiangsu Hualv Biological Technology Co.Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Jiangsu Hualv Biological Technology Co.Ltd. generates 0.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Jiangsu Hualv Biological Technology Co.Ltd. is currently not profitable relative to its asset base.
Jiangsu Hualv Biological Technology Co.Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.00 | 2.62 | 4.98 |
| Quick Ratio | 1.94 | 1.72 | 4.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥384.28 Million | CN¥ 325.48 Million | CN¥ 740.02 Million |
Jiangsu Hualv Biological Technology Co.Ltd. - Advanced Valuation Insights
This section examines the relationship between Jiangsu Hualv Biological Technology Co.Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.89 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 8.8% |
| Total Assets | CN¥2.31 Billion |
| Market Capitalization | $227.54 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Hualv Biological Technology Co.Ltd.'s assets below their book value (0.10 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jiangsu Hualv Biological Technology Co.Ltd.'s assets grew by 8.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jiangsu Hualv Biological Technology Co.Ltd. (2019–2024)
The table below shows the annual total assets of Jiangsu Hualv Biological Technology Co.Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.31 Billion | +8.80% |
| 2023-12-31 | CN¥2.12 Billion | +7.00% |
| 2022-12-31 | CN¥1.98 Billion | +5.53% |
| 2021-12-31 | CN¥1.88 Billion | +61.11% |
| 2020-12-31 | CN¥1.16 Billion | +14.44% |
| 2019-12-31 | CN¥1.02 Billion | -- |